Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Cancer Med. 2024 Jan;13(1):e6863. doi: 10.1002/cam4.6863. Epub 2023 Dec 22.
Near-infrared photoimmunotherapy (NIR-PIT) for head and neck cancer is a recently developed therapy. However, there is limited data on patients receiving NIR-PIT in real clinical settings.
Seven NIR-PIT sessions were administered to five patients with head and neck squamous cell carcinoma (HNSCC). Serum damage-associated molecular patterns (DAMPs) (HMGB1 and Hsp70 levels), and cytokine and chemokine production, were compared before and after NIR-PIT.
The serum concentration of HMGB1 increased after NIR-PIT (p = 0.031, Wilcoxon test) in all patients except one who did not achieve a clinical response. Chemokines MIP-1α (CCL3) and MIP-1β (CCL4) increased significantly 1-3 days after treatment (CCL3, p = 0.0036; CCL4, p = 0.0016, Wilcoxon test). A low pre-treatment neutrophil-to-lymphocyte ratio (NLR) was associated with a better response to therapy and survival.
The release of DAMPs, and cytokine/chemokine production, were detected in the patients' peripheral blood. The baseline NLR may predict patient outcomes in response to NIR-PIT.
近红外光免疫治疗(NIR-PIT)是一种新兴的头颈部癌症治疗方法。然而,在真实临床环境中,接受 NIR-PIT 治疗的患者的数据有限。
5 例头颈部鳞状细胞癌(HNSCC)患者接受了 7 次 NIR-PIT 治疗。比较 NIR-PIT 前后血清损伤相关分子模式(DAMPs)(HMGB1 和 Hsp70 水平)和细胞因子及趋化因子的产生情况。
除 1 例未达到临床缓解的患者外,所有患者的血清 HMGB1 浓度在 NIR-PIT 后均升高(p=0.031,Wilcoxon 检验)。趋化因子 MIP-1α(CCL3)和 MIP-1β(CCL4)在治疗后 1-3 天显著增加(CCL3,p=0.0036;CCL4,p=0.0016,Wilcoxon 检验)。治疗前较低的中性粒细胞与淋巴细胞比值(NLR)与更好的治疗反应和生存相关。
在患者外周血中检测到 DAMPs 的释放和细胞因子/趋化因子的产生。基线 NLR 可能预测患者对 NIR-PIT 治疗的反应和预后。